ABCL(ABCL)
ABCL
ANALYST COVERAGE11 analysts
BUY
▲ +45.9%upside to target
L $7.00
Med $7.50consensus
H $8.00PRICE
Prev Close
4.57
Open
4.45
Day Range4.45 – 5.43
4.45
5.43
52W Range1.94 – 6.52
1.94
6.52
70% of range
VOLUME & SIZE
Avg Volume
5.4M
FUNDAMENTALS
P/E Ratio
-10.7x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.36
Market-like
TECHNICAL
RSI (14)
45
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 22
DEx-Dividend
In 90 days
Aug 19
PDividend Pay
In 120 days
Sep 18
ABCL News
About
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development.
Caitlin Webster CIPDDirector of Talent Development
Carl HansenChief Executive Officer, President & Chairperson
Veronique LecaultChief Technology Officer & Director
Adam ClarkeSenior Vice President of Discovery
Martin HoganSenior Director of Strategic Finance & IR
Murray McCutcheonSenior Vice President of Partnering
Tryn T. StimartChief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer
Tiffany ChiuVice President of Communications
Marcie ThiessenSenior Director of Finance & Accounting
Andrew BoothChief Financial Officer
Andrew KnowlesVice President of Operations